Repertoire Immune Medicines and Bristol Myers Squibb Enter $1.865B Collaboration to Develop Tolerizing Vaccines for Three Autoimmune Diseases

Repertoire® Immune Medicines announced that the company has entered intoBristol-Myers Squibb(BMS) reached a multi-year strategic cooperation to jointly develop up to three types of autoimmuneImmunityTolerizing vaccines for sexually transmitted diseases. This collaboration aims to develop effective, selective, and long-lasting treatments for patients with autoimmune diseases by resetting the immune system.

According to the terms of the agreement, in addition to receiving tiered royalties, Repertoire will receive a $65 million upfront payment and up to $1.8 billion in development, regulatory, and commercial milestone payments.

Repertoire Immune Medicines will lead all activities until the drug candidate is selected by Bristol-Myers Squibb (BMS), and BMS will obtain the global exclusive rights for the development and commercialization of the tolerogenic vaccine. The company will utilize its T-cell receptor (TCR) epitope discovery platform, DECODE, along with its proprietary lipid nanoparticle delivery technology, to discover and develop tolerogenic vaccine candidates. Additionally, during clinical development, the company will deploy DECODE to monitor patients' immune responses to the vaccine, providing critical insights into the pharmacodynamic effects of the vaccine.

"This agreement is a recognition of Repertoire's DECODE platform in discovering and developing programmable T-cell targetingImmunological Drugs"Recognition of the transformative power in this area," said Dr. Torben Straight Nissen, CEO of Repertoire Immune Medicines and Executive Partner at Flagship Pioneering. "We are excited to collaborate with Bristol-Myers Squibb, combining their leadership in immunology with our unique ability to identify critical disease-related epitopes in patients with autoimmune diseases. This collaboration allows us to address the root causes of autoimmune diseases by translating our DECODE discoveries into potentially transformative drugs, thereby serving patients suffering from autoimmune conditions."